Related Experiment Video
Updated: Mar 21, 2026
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
[Immunomodulation and neuroprotection in optic neuritis]
1Universitäts-Augenklinik Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Deutschland. flemming.beisse@med.uni-heidelberg.de.
Background:
To date, high-dose corticosteroids constitute the only established treatment of acute optic neuritis (ON); however, steroids cannot prevent the loss of retinal nerve fibers. New acute therapeutic drugs are therefore being sought for a reduction of ganglion cell death.
Methods:
Literature search comprising clinical studies on treatment of ON with immunomodulatory and neuroprotective drugs.
Results:
For the immunomodulatory drug simvastatin some evidence for long-term benefits was shown, particularly regarding visual evoked potentials. For the neuroprotective substance memantine a potential positive effect on retinal nerve fiber layer (RNFL) thickness was revealed. Likewise in one publication a reduction in loss of RNFL thickness could be demonstrated for erythropoietin and this drug is currently being extensively investigated in a phase III randomized controlled trial (RCT). The results of studies with phenytoin, amiloride and anti-leucine-rich repeat and immunoglobulin domain containing 1 protein (anti-LINGO-1) antibodies are awaiting publication.
Conclusion:
According to the data from recent treatment trials, there is hope that neuronal loss in ON can be reduced with the help of immunomodulatory substances, such as simvastatin or neuroprotective agents, such as memantine and erythropoietin.
Insights
New treatments for optic neuritis (ON) show promise in preventing nerve cell loss. Immunomodulatory and neuroprotective drugs like simvastatin, memantine, and erythropoietin may reduce neuronal damage beyond current corticosteroid therapies.
Area of Science:
- Ophthalmology
- Neuroscience
- Pharmacology
Background:
- Acute optic neuritis (ON) treatment primarily relies on high-dose corticosteroids.
- Corticosteroids do not prevent retinal nerve fiber loss in ON.
- There is a critical need for novel therapeutics to mitigate ganglion cell death in ON.
Purpose of the Study:
- To review current literature on immunomodulatory and neuroprotective drugs for acute optic neuritis (ON) treatment.
- To assess the potential of novel agents to reduce neuronal loss in ON.
- To identify emerging therapeutic strategies beyond corticosteroids.
Main Methods:
- Comprehensive literature search of clinical studies.
- Focus on treatments for optic neuritis (ON) using immunomodulatory and neuroprotective agents.
- Analysis of evidence for efficacy and impact on neuronal survival.
Main Results:
- Simvastatin (immunomodulatory) shows potential long-term benefits, particularly on visual evoked potentials.
- Memantine (neuroprotective) may positively impact retinal nerve fiber layer (RNFL) thickness.
- Erythropoietin demonstrated a reduction in RNFL thickness loss and is under extensive Phase III investigation. Results for phenytoin, amiloride, and anti-LINGO-1 are pending.
Conclusions:
- Emerging data suggest immunomodulatory and neuroprotective drugs offer hope for reducing neuronal loss in ON.
- Agents like simvastatin, memantine, and erythropoietin represent promising therapeutic avenues.
- Further research and clinical trials are essential to confirm the efficacy of these novel treatments for ON.
